OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial
ONCOMED PHARMACEUTICALS (OMED)
Last oncomed pharmaceuticals earnings: 11/1 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
oncomed.com/invest/index.cfm
Company Research
Source: GlobeNewswire
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1 REDWOOD CITY, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the first patient has been dosed in the company’s Phase 1b portion of the Phase 1a/1b clinical trial of anti-TIGIT (OMP-313M32) in combination with anti-PD1 (nivolumab). TIGIT (T-cell immunoreceptor with Ig and ITIM domains) is a next generation checkpoint receptor, and upon activation by the PVR ligand, a protein broadly expressed on tumor cells, it blocks T-cell activation. OncoMed’s anti-TIGIT candidate is an IgG1 monoclonal antibody checkpoint inhibitor which binds to the human TIGIT receptor on T-cells with a goal of improving the activation and effectiveness of T-cell and NK cell tumor-killing activity. “The dosing of the first patient in the Phase 1b portion of the anti
Show less
Read more
Impact Snapshot
Event Time:
OMED
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OMED alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OMED alerts
High impacting ONCOMED PHARMACEUTICALS news events
Weekly update
A roundup of the hottest topics